1. Show article details.

    Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union

    GlobeNewswire – 12:10 PM ET 10/04/2021

    NEW YORK and MAINZ, Germany, October 4, 2021—Pfizer Inc. and BioNTech SE (BNTX) today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18 years of age and older.

  2. Show article details.

    BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting

    GlobeNewswire – 8:12 AM ET 10/01/2021

    MAINZ, Germany, October 1, 2021 -- BioNTech SE (BNTX), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today announced that new clinical and preclinical data will be presented in six posters and one presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, being held both in person and virtually from November 10 - 14, 2021.

  3. Show article details.

    Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)

    Business Wire – 8:00 AM ET 10/01/2021

    COPENHAGEN, Denmark---- Genmab A/S (GMAB) announced today that multiple abstracts evaluating several investigational therapies and technologies in the company’s solid tumor product pipeline will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, being held in Washington, DC, and virtually, November 10-14.

  4. Show article details.

    BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

    GlobeNewswire – 2:00 AM ET 10/01/2021

    MAINZ, GERMANY, October 1, 2021 – BioNTech SE (BNTX), announced today that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 in a Phase 2 clinical trial. The open-label Phase 2 trial is investigating autogene cevumeran in stage II/III colorectal cancer patients after surgical resection of their tumor and completion of adjuvant chemotherapy.

  5. Show article details.

    Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age

    Business Wire – 6:45 AM ET 09/28/2021

    Formal submission to request Emergency Use Authorization to follow in the coming weeks Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced they have submitted data to the U.S. Food and Drug Administration from the Phase 2/3 trial of their COVID-19 vaccine in children 5 to <12 years of age. This press release features multimedia.￿

  6. Show article details.

    Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster

    Business Wire – 9:44 PM ET 09/22/2021

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced that the U.S. Food and Drug Administration has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose frequent institutional or oc...

  7. Show article details.

    Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries

    GlobeNewswire – 6:02 AM ET 09/22/2021

    NEW YORK and MAINZ, Germany, September 22, 2021—Pfizer Inc. and BioNTech SE (BNTX) today announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies’ COVID-19 vaccine at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them.

  8. Show article details.

    Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries

    Business Wire – 6:02 AM ET 09/22/2021

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies’ COVID-19 vaccine at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them. This press release features multimedia.

  9. Show article details.

    Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years

    GlobeNewswire – 6:45 AM ET 09/20/2021

    NEW YORK and MAINZ, Germany, September 20, 2021—Pfizer Inc. and BioNTech SE (BNTX) today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older.

  10. Show article details.

    Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years

    Business Wire – 6:45 AM ET 09/20/2021

    NEW YORK AND MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older. This press release features multimedia.

  11. Show article details.

    FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

    GlobeNewswire – 3:40 AM ET 09/18/2021

    NEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. and BioNTech SE (BNTX) announced today that the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted unanimously to recommend the FDA grant Emergency Use Authorization for a booster dose of COMIRNATY® in individuals 65 years of age and older and individuals at high risk of severe COVID-19.

  12. Show article details.

    FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations

    Business Wire – 7:21 PM ET 09/17/2021

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced today that the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted unanimously to recommend the FDA grant Emergency Use Authorization for a booster dose of COMIRNATY® in individuals 65 years of age and older and individuals at high risk of severe COVID-19.

  13. Show article details.

    European Medicines Agency Approves Additional Manufacturing Sites for Pfizer-BioNTech Covid Vaccine

    DJ Business News – 12:41 PM ET 09/09/2021

    The European Medicines Agency said Thursday that it has approved two additional manufacturing sites for the production of the Covid-19 vaccine developed by Pfizer Inc. (PFE) and BioNTech SE (BNTX). The sites, which will manufacture the finished product, are set to provide up to 50 million additional doses of Comirnaty by 2021, according to the EU agency. One site is operated by Sanofi-Aventis Deutschland GmbH, while the other by Siegfried Hameln GmbH.

  14. Show article details.

    VC Daily: Laronde Fundraising Haul Reflects Search for Next Moderna

    DJ Business News – 9:49 AM ET 09/02/2021

    RNA-drug startup Laronde's new $440 million fundraising reflects investors' search for the next Moderna Inc. (MRNA). Flagship Pioneering formed Moderna (MRNA) in 2010 to use messenger RNA to program patients' cells to make disease-fighting proteins. Moderna (MRNA), which went public in 2018, fulfilled that promise by developing its Covid-19 vaccine.

  15. Show article details.

    Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply

    GlobeNewswire – 7:15 AM ET 08/27/2021

    BERLIN, GERMANY, August 27, 2021 – BioNTech SE (BNTX) agreed today to evaluate the establishment of sustainable vaccine manufacturing capabilities in Rwanda and Senegal to support vaccine supply for the Member States of the African Union. “We would like to thank all participants for today’s discussion and for the support and trust they put in us.

  16. Show article details.

    Pfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America

    GlobeNewswire – 6:46 AM ET 08/26/2021

    NEW YORK, USA and MAINZ, GERMANY, August 26, 2021 — Pfizer Inc. and BioNTech SE (BNTX) today announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture COMIRNATY® for distribution within Latin America.

  17. Show article details.

    Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America

    Business Wire – 6:45 AM ET 08/26/2021

    Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture COMIRNATY® for distribution within Latin America. This press release features multimedia.

  18. Show article details.

    Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older

    GlobeNewswire – 12:10 PM ET 08/25/2021

    NEW YORK, USA and MAINZ, GERMANY, August 25, 2021 — Pfizer Inc. and BioNTech SE (BNTX) today announced the initiation of a supplemental Biologics License Application to the U.S. Food and Drug Administration for the approval of a booster dose of COMIRNATY® to prevent COVID-19 in individuals 16 years of age and older.

  19. Show article details.

    Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older

    Business Wire – 12:08 PM ET 08/25/2021

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced the initiation of a supplemental Biologics License Application to the U.S. Food and Drug Administration for the approval of a booster dose of COMIRNATY® to prevent COVID-19 in individuals 16 years of age and older. This press release features multimedia.

  20. Show article details.

    Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older

    Business Wire – 11:57 AM ET 08/23/2021

     . NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced that the U.S. Food and Drug Administration approved the Biologics License Application for COMIRNATY® to prevent COVID-19 in individuals 16 years of age and older. This press release features multimedia. The vaccine has been available in the U.S. under Emergency Use Authorization since December 11, 2020.

Page:

Today's and Upcoming Events

  • Nov
    09

    BNTX to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Aug
    09

    BNTX announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.